BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26802605)

  • 21. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine.
    Ainai A; Ichinohe T; Tamura S; Kurata T; Sata T; Tashiro M; Hasegawa H
    J Med Virol; 2010 Mar; 82(3):476-84. PubMed ID: 20087927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal co-administration of 1,8-cineole with influenza vaccine provide cross-protection against influenza virus infection.
    Li Y; Xu YL; Lai YN; Liao SH; Liu N; Xu PP
    Phytomedicine; 2017 Oct; 34():127-135. PubMed ID: 28899494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.
    Das SC; Hatta M; Wilker PR; Myc A; Hamouda T; Neumann G; Baker JR; Kawaoka Y
    Vaccine; 2012 Nov; 30(48):6871-7. PubMed ID: 22989689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of lung CD8
    Moriyama M; Takeyama H; Hasegawa H; Ichinohe T
    Vaccine; 2017 Dec; 35(48 Pt B):6620-6626. PubMed ID: 29079103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.
    Ichinohe T; Ainai A; Ami Y; Nagata N; Iwata N; Kawaguchi A; Suzaki Y; Odagiri T; Tashiro M; Takahashi H; Strayer DR; Carter WA; Chiba J; Tamura S; Sata T; Kurata T; Hasegawa H
    J Med Virol; 2010 Oct; 82(10):1754-61. PubMed ID: 20827774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
    Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
    PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.
    Kimoto T; Mizuno D; Takei T; Kunimi T; Ono S; Sakai S; Kido H
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1218-26. PubMed ID: 23710832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P; Hedenskog M; Alves D; Brytting M; Schröder U; Linde A; Lundkvist A
    Vaccine; 2010 Sep; 28(39):6491-7. PubMed ID: 20637767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
    Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants.
    Dehghan S; Tafaghodi M; Bolourieh T; Mazaheri V; Torabi A; Abnous K; Tavassoti Kheiri M
    Int J Pharm; 2014 Nov; 475(1-2):1-8. PubMed ID: 25148732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.
    Ichinohe T; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Ninomiya A; Imai M; Itamura S; Odagiri T; Tashiro M; Chiba J; Sata T; Kurata T; Hasegawa H
    Microbes Infect; 2007 Sep; 9(11):1333-40. PubMed ID: 17890128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.